Haematologica 2018 May 24
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.
Related Questions
Ki67 = 90% with multiple small nodes on PET scan and normal CBC
New answer by Medical Oncologist at City of Hope (November 14, 2021)
While p53 mutations are known to impact clinical outcome after administration of cytotoxic chemotherapy in frontline MCL (Eskelund et al., PMID 29794145, Elhassadi E et al. Pr...